Radioactive Microspheres Show Real-World Promise Against Hard-to-Treat Liver Metastases

When cancer spreads to the liver, the outlook is often grim, and for tumors that did not start in the colon, treatment options have long been murky. Now one of the largest real-world studies of its kind suggests that a therapy which fires millions of microscopic radioactive beads directly into liver tumors may be both safe and effective across a surprisingly wide range of cancers. The findings, drawn from a prospective European registry, offer the clearest picture yet of how transarterial radioembolization, or TARE, performs outside the colorectal cancer setting where it is already established.

The study, published in CVIR Oncology, analyzed data from the CIRSE Registry for SIR-Spheres Therapy, known as CIRT, a Europe-wide observational study conducted in eight countries across 27 centers. Of the 1,036 patients enrolled with primary or secondary liver malignancies, the researchers focused on 169 adults whose liver metastases originated from neuroendocrine tumors, breast cancer, pancreatic cancer, or melanoma. All were treated with yttrium-90 resin microspheres, tiny radioactive spheres delivered through the hepatic artery that lodge in the small vessels feeding tumors and deliver high-dose internal radiation while sparing most healthy tissue.

The technical logic behind TARE is elegant. Unlike conventional external beam radiotherapy, which must pass through healthy tissue to reach its target, radioembolization exploits the fact that liver tumors draw their blood supply predominantly from the hepatic artery, while healthy liver tissue depends on the portal vein. Catheters threaded from a puncture in the groin or wrist guide the microspheres into the arteries supplying the tumors, where the beta radiation from yttrium-90, which travels only a few millimeters in tissue, kills cancer cells from within. Before treatment, teams perform careful mapping angiography and dosimetry, often using the body surface area method or a partition model, to calculate the activity to be injected and to avoid reflux of spheres into the stomach or bowel.

The survival results varied dramatically by tumor type, underscoring how different these diseases are. Patients with neuroendocrine tumors fared best, with a median overall survival of 33.3 months after treatment. Those with breast cancer liver metastases had a median survival of 10.7 months, while patients with melanoma reached 14.7 months. Pancreatic cancer, notoriously aggressive even when it has spread only to the liver, showed the poorest outcome at 5.6 months. Median follow-up ranged from 5.6 months in the pancreatic cohort to 19.3 months in the neuroendocrine group, and patients were enrolled between January 2015 and December 2017 with follow-up through the end of 2019.

Safety was the study’s most consistent message. Severe adverse events of grade three or higher, defined according to the standard CTCAE criteria, occurred in just 10 percent of all 169 patients. Procedure-related adverse events were predominantly mild to moderate, affecting roughly one in five neuroendocrine and breast cancer patients and only about six percent of those with pancreatic cancer or melanoma. Predefined serious events tracked in the registry included abdominal pain, fatigue, fever, nausea, vomiting, gastrointestinal ulceration, gastritis, and radiation cholecystitis, but these remained uncommon. For a therapy that delivers ionizing radiation directly into a vital organ, this safety profile across four very different tumor types is a notable result.

Perhaps the most scientifically intriguing findings came from the multivariable analysis, in which the researchers used Cox proportional hazards models to identify independent predictors of survival. Two laboratory-based markers emerged repeatedly. The Albumin-Bilirubin grade, or ALBI, which combines liver synthetic function with bile clearance, predicted worse overall survival in both the neuroendocrine and breast cancer cohorts, with hazard ratios above four. The Aspartate transaminase to Platelet Ratio Index, or APRI, a marker usually associated with liver fibrosis, predicted poorer survival in the neuroendocrine and melanoma cohorts. In melanoma patients the effect was striking: an APRI value above 0.40 carried a hazard ratio of 37.63 for death, an extraordinarily strong association. In breast cancer patients, an international normalized ratio above one and an elevated neutrophil-to-leukocyte ratio also predicted worse progression-free survival.

These biomarker findings carry practical weight. They suggest that the health of the underlying liver, and possibly the systemic inflammatory state reflected in blood counts, shapes how much patients benefit from internal radiation, and that the relevant markers differ by tumor type. The authors argue this supports individualized patient assessment that incorporates both the histology of the metastases and routine laboratory evaluation. It also hints that simple blood tests available before treatment could help clinicians select which patients are most likely to benefit, an increasingly important question as liver-directed therapies proliferate.

Context matters for interpreting the survival numbers. For neuroendocrine liver metastases, which develop in up to 80 percent of patients with these tumors, the 33.3 month median survival aligns closely with a systematic review of 809 patients that reported a pooled overall survival of 33 months, and with the American RESiN registry, which reported a median of 33 months. For breast cancer, the 10.7 month result is comparable to a meta-analysis of 452 patients that found a median of 11.3 months. In melanoma, where nearly 60 percent of the study’s patients received TARE as first-line liver-directed therapy, the 14.7 month median sits comfortably within the 9 to 24 month range reported across systematic reviews of radioembolization for uveal melanoma. The pancreatic cancer result, while bleak, reflects a disease in which even surgery and modern chemotherapy yield median survivals under a year in the metastatic liver setting.

The study’s authors are careful about its limits. As an observational registry without a control group, it cannot prove that TARE is superior to other options, and selection bias and residual confounding cannot be excluded. The lack of a standardized treatment protocol across 27 centers introduced heterogeneity in baseline characteristics, treatment timing, and surrounding systemic therapies. Missing data may have affected some analyses, and no multivariable model was possible for the pancreatic cohort because too few variables reached the significance threshold. What the study does provide is something rarer: prospectively collected, multicenter, real-world evidence about how TARE is actually used and how patients actually fare when multidisciplinary teams choose it for tumors that fall outside existing guidelines.

That guideline gap is precisely why the results matter. TARE is a standard of care for intermediate to advanced hepatocellular carcinoma and for metastatic colorectal cancer, but for non-colorectal liver metastases, formal recommendations have been largely absent; the European Neuroendocrine Tumour Society recently noted that no data existed on liver embolization for neuroendocrine carcinoma. By documenting safety and encouraging effectiveness in 169 patients across four tumor types, the CIRT analysis gives clinicians a firmer evidence footing for a treatment many were already offering, and it sets a clear agenda: prospective comparative studies are now needed to identify which patient groups benefit most, and simple markers like ALBI and APRI may help decide who should be offered the radioactive beads and who should be spared the procedure.

Subject of Research: Yttrium-90 transarterial radioembolization for non-colorectal liver metastases

Article Title: Transarterial radioembolization for liver metastases of non-colorectal origin: safety and effectiveness results from the prospective multicenter CIRSE registry for SIR-spheres therapy (CIRT)

Article References: Arnold, D., Chlorogiannis, D. D., Sangro, B., Kolligs, F., Maleux, G., Bilbao, J. I., Pech, M., Pfammatter, T., de Jong, N., Geyer, M., Urdániz, M., & Helmberger, T. (2026). Transarterial radioembolization for liver metastases of non-colorectal origin: safety and effectiveness results from the prospective multicenter CIRSE registry for SIR-spheres therapy (CIRT). CVIR Oncology, 2(1), Article 6. https://doi.org/10.1007/s44343-026-00039-1

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00039-1

Keywords: transarterial radioembolization, yttrium-90, liver metastases, neuroendocrine tumors, breast cancer, pancreatic cancer, melanoma, SIR-Spheres, CIRT registry, ALBI grade, APRI, interventional radiology